Clinical trials: Diabetes, Type 1
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of this clinical trial is to investigate the effect of NN1250 (insulin degludec) in Japanese subjects with type 1 diabetes.
- Trial name
- NCT01135927
- Testing
- insulin degludec, insulin detemir
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
- Trial name
- NCT02580591
- Testing
- Empagliflozin
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 977 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Long-Term Outcomes of Teplizumab in Routine Clinical Care
This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D.
- Trial name
- AL1GN (NCT07360080)
- Testing
- Teplizumab
- Where
- 10 sites in United States, Israel and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Insulin-dependent Diabetes Mellitus, Diabetes Mellitus, Type 1
DreaMed Advisor Pro System in Subjects With Type 1 Diabetes Treated With MDI Therapy
A multi center, open label, prospective study that will include up to 100 subjects with Type 1 Diabetes treated with Multiple Daily Injections (MDI) of insulin according to a predefined sliding scale plan or carbohydrate ratio…
- Trial name
- NCT04043260
- Testing
- Advisor Pro
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- DreaMed Diabetes
Type 1 Diabetes Mellitus
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System
This study is a Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects.
- Trial name
- NCT03959423
- Testing
- AHCL insulin pump system
- Where
- 17 sites in United States
- Volunteers
- 288 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
This is an open-label study that will measure blood levels of different parts of a drug called GKS189075. People participating in this study will receive a single dose of 250mg GSK189075 by mouth.
- Conditions
- Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency
- Trial name
- NCT00501462
- Testing
- GSK189075
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Diabetes Mellitus, Type 1
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm
The purpose of this multi-center, prospective clinical study is to evaluate the performance of a novel, implanted Senseonics continuous glucose monitoring system (Senseonics CGM System) compared to Yellow Springs Instrument (YSI)…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PRECISION (NCT03251079)
- Testing
- Continuous glucose monitoring system
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Senseonics, Inc.
Type 1 Diabetes Mellitus
Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin
The purpose of this study is to determine if glucose peaks higher and earlier after a meal when a patient is given intranasal insulin instead of conventional insulin treatment.
- Trial name
- NCT00850161
- Testing
- aspart, Nasulin™
- Sponsor
- CPEX Pharmaceuticals Inc.
Type 1 Diabetes
Investigation of Hyposafe H02 Device in Patients With Type 1 Diabetes
This clinical study is designed to collect data for further development of a hypoglycaemia notification algorithm. In addition, information regarding safety will be collected and analysed.
- Trial name
- NCT05495386
- Testing
- Hyposafe hypoglycaemia notification device (H02)
- Sponsor
- UNEEG Medical A/S
Type 1 Diabetes
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years.
- Trial name
- RescuiNGkids (NCT04992312)
- Testing
- Glucagon Nasal Powder [Baqsimi]
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Primary objective: To evaluate the safety and tolerability of single and multiple ascending doses of PB1023 administered as a subcutaneous (SC) injection in adult subjects with T2DM. Secondary objectives: 1.
- Trial name
- NCT01236404
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Type 1 Diabetes Mellitus
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
Primary Objective: -To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT02527265
- Testing
- Afrezza
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
Type 1 Diabetes
Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes
The goal of this clinical trial is to assess safety of and explore glycemic outcomes with Control-IQ technology 2.0 in adults, children and preschoolers with type 1 diabetes.
- Trial name
- NCT05683392
- Testing
- t:slim X2 insulin pump with Control-IQ technology 2.0
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Type 2 Diabetes Mellitus
Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus
This protocol is intended to compare the effects of both a solid (tablet) and liquid oral dosage form of LX4211 in subjects with type 2 diabetes mellitus.
- Trial name
- NCT01188863
- Testing
- 300 mg LX4211 (150 mg tablets), 300 mg LX4211 (50 mg tablets), 300 mg LX4211 (liquid)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Type 2
Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes
Twelve smoking and twelve non-smoking subjects with Type 2 Diabetes Mellitus will be enrolled in this study to determine the effect of Technosphere® Insulin Inhalation Powder on insulin in the body during a clamp procedure.
- Trial name
- NCT00934414
- Testing
- Technosphere Insulin Inhalation Powder
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mannkind Corporation
Type 1 Diabetes Mellitus
A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)
The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.
- Trial name
- NCT01686620
- Testing
- BIOD-123, Lispro (Humalog)
- Where
- 34 sites in United States
- Volunteers
- 132 people
- Sponsor
- Biodel
T1D
Validation of a Computerised Adaptive Test for Measuring Caregiver Well-being
The main objective of this project is to test whether a tool (questionnaire) is suitable for assessing how caregivers of children and adolescents with TD1 feel emotionally and psychologically.
- Trial name
- NCT06999486
- Testing
- CAT well-being test
- Where
- Spain
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Type 1 Diabetes Mellitus
Bigfoot Biomedical Clinical Research Center (CRC) Trial
The trial is designed to assess safety and feasibility of the Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS) in up to 50 participants in a closely monitored Clinical Research Center (CRC) environment.
- Trial name
- NCT02849288
- Testing
- Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Bigfoot Biomedical Inc.
Diabetes
Effect of Glucose on QTc Interval in Type 1 Diabetes
High blood glucose levels (hyperglycaemia) and Moxifloxacin (a commonly used antibiotic) have both been shown independently to affect heart activity in healthy volunteers as recorded by ECG. i.e.
- Trial name
- NCT01984827
- Testing
- Moxifloxacin, hyper-glycaemic clamp
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Richmond Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.